News Roche inks pipeline deals with Orionis, PeptiDream Roche has bolstered its R&D pipeline in oncology and neuroscience with a pair of partnerships with Orionis Biosciences and PeptiDream, parting with upfront cash of $87
News Astellas builds in protein degraders with PeptiDream deal Astellas has made another move into the area of protein degrader drugs, announcing its second partnership in the category in the space of two months.
News FDA clears Viridian's Tepezza rival for thyroid eye disease Viridian has fired a shot across Amgen's bows with the FDA approval of Tepezza rival Lumvoa in thyroid eye disease, a $2bn market.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.